GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (HKSE:01466) » Definitions » Debt-to-EBITDA

Baijin Life Science Holdings (HKSE:01466) Debt-to-EBITDA : 6.29 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Baijin Life Science Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Baijin Life Science Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was HK$12.72 Mil. Baijin Life Science Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was HK$53.00 Mil. Baijin Life Science Holdings's annualized EBITDA for the quarter that ended in Sep. 2024 was HK$10.45 Mil. Baijin Life Science Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 6.29.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Baijin Life Science Holdings's Debt-to-EBITDA or its related term are showing as below:

HKSE:01466' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.1   Med: -0.69   Max: 154.98
Current: 154.98

During the past 11 years, the highest Debt-to-EBITDA Ratio of Baijin Life Science Holdings was 154.98. The lowest was -8.10. And the median was -0.69.

HKSE:01466's Debt-to-EBITDA is ranked worse than
99.77% of 874 companies
in the Retail - Cyclical industry
Industry Median: 2.625 vs HKSE:01466: 154.98

Baijin Life Science Holdings Debt-to-EBITDA Historical Data

The historical data trend for Baijin Life Science Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings Debt-to-EBITDA Chart

Baijin Life Science Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.69 -3.27 0.25 -8.10

Baijin Life Science Holdings Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 -2.19 -1.11 -5.33 6.29

Competitive Comparison of Baijin Life Science Holdings's Debt-to-EBITDA

For the Luxury Goods subindustry, Baijin Life Science Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baijin Life Science Holdings's Debt-to-EBITDA Distribution in the Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Baijin Life Science Holdings's Debt-to-EBITDA falls into.



Baijin Life Science Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Baijin Life Science Holdings's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.533 + 40.66) / -6.324
=-8.10

Baijin Life Science Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.717 + 52.995) / 10.446
=6.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2024) EBITDA data.


Baijin Life Science Holdings  (HKSE:01466) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Baijin Life Science Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Baijin Life Science Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Baijin Life Science Holdings Business Description

Traded in Other Exchanges
Address
66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.
Executives
Pacific Wish Limited
Chan Vincent Wing Sing
Hui Ka Man Emily
Su Yaoyao 2201 Interest of corporation controlled by you
Ketto Inform Limited 2101 Beneficial owner

Baijin Life Science Holdings Headlines

No Headlines